000			01937nam a2200301Ia 4500
003			MX-MdCICY
005			20250625162436.0
040			_cCICY
090			_aB-19773
245	1	0	_aPHLPPs: Emerging players in metabolic disorders
490	0		_vDrug Discovery Today, 27(10), p.1-11, 2022
520	3		_aThat reversible protein phosphorylation by kinases and phosphatases occurs in metabolic disorders is well known. Various studies have revealed that a multi-faceted and tightly regulated phosphatase, pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP)-1/2 displays robust effects in cardioprotection, ischaemia/reperfusion (I/R), and vascular remodelling. PHLPP1 promotes foamy macrophage development through ChREBP/AMPK-dependent pathways. Adipocyte-specific loss of PHLPP2 reduces adiposity, improves glucose tolerance,and attenuates fatty liver via the PHLPP2-HSL-PPAR? axis. Discoveries of PHLPP1-mediated insulin resistance and pancreatic ? cell death via the PHLPP1/2-Mst1-mTORC1 triangular loop have shed light on its significance in diabetology. PHLPP1 downregulation attenuates diabetic cardiomyopathy (DCM)by restoring PI3K-Akt-mTOR signalling. In this review, we summarise the functional role of, and cellular signalling mediated by, PHLPPs in metabolic tissues and discuss their potential as therapeutic targets.
650	1	4	_aPHLPP1
650	1	4	_aPHLPP2
650	1	4	_aTYPE 2 DIABETES
650	1	4	_aCARDIOVASCULAR DYSFUNCTION
650	1	4	_aATHEROSCLEROSIS
700	1	2	_aBalamurugan, K.
700	1	2	_aChandra, K.
700	1	2	_aLatha, S. S.
700	1	2	_aSwathi, M.
700	1	2	_aJoshi, M. B.
700	1	2	_aMisra, P.
700	1	2	_aParsa, K. V.
856	4	0	_uhttps://drive.google.com/file/d/1CbE8FcZu8GG-_UdOqtU8A4Z4xs04r-v_/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c53892 _d53892